Related Experiment Video
Updated: Jul 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Antiandrogens in the treatment of prostate cancer
Manfred P Wirth1, Oliver W Hakenberg, Michael Froehner
1Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany. Manfred.Wirth@uniklinikum-dresden.de <Manfred.Wirth@uniklinikum-dresden.de>
Objectives:
To give an overview on the contemporary role of antiandrogens in prostate cancer treatment.
Methods:
A review of the literature was performed concerning pharmacologic properties, possible indications and side effects of antiandrogens in the treatment of early and advanced prostate cancer.
Results:
One steroidal and three non-steroidal antiandrogens are in common use for the treatment of prostate cancer. Monotherapy with non-steroidal antiandrogens may prevent osteoporosis, loss of musculature and may preserve sexual activity in a proportion of patients and therefore has advantages in quality of life compared to castration. In patients with localized disease managed by watchful waiting or in an adjuvant setting, there are no studies showing an advantage in early versus delayed treatment with antiandrogens regarding clinical progression. In locally advanced non-metastatic prostate cancer, antiandrogen monotherapy seems to be an alternative to castration treatment if treatment is required. In patients with metastatic disease and a high tumor burden, antiandrogen monotherapy is inferior to castration. In advanced disease, combined androgen blockade can provide a small survival advantage, which, however, has to be balanced against increased side effects and costs.
Conclusions:
Antiandrogens are a treatment option in some patients with prostate cancer. However, it has to be taken into account that the hormonal effect is inferior to castration.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
